BLOOD 2021: The TKI Gilteritinib Maintains Remission of FLT3-Mutated R/R AML
Safety appeared stable after 2 years.
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Safety appeared stable after 2 years.
Only registered members have full access to PracticeUpdate content.